Moderna: Revenue Surprise and Cancer Pipeline – The Starting Signal for Re-evaluation Has Been Given!

Moderna defies the swan song of the post-Covid era and significantly exceeds Wall Street expectations with revenue of USD 678 million in Q4. The biotech company from Cambridge, Massachusetts, was well above the average analyst estimates of USD 626 million. Following the massive drop in demand for Covid vaccines, the company is under pressure to prove the long-term viability of its mRNA technology through new products. The management is responding to the financial challenges with a strict growth focus and reaffirmed its expectation of a 10% revenue...